Director

Yusuke Tominari is responsible for the overall success of a business entity or other organization and for making top-level managerial decisions as a CEO. He launched FIMECS with his colleagues in 2018 as a curve-out biotech from Takeda Pharmaceutical Company Limited. He started his career of a medicinal chemist at Takeda in 2006 after getting a Ph.D. at the University of Tokyo in Japan. His expertise is medicinal chemistry in immunology, oncology and immuno-oncology areas, Natural product synthesis and Chemical biology (Bifunctional molecules, Photo-affinity labeling probes, Cleavable linkers and others). Through his thirteen years of the pharmaceutical experience, he has contributed 2 out-licensing and 1 IND filing as a leader of medicinal chemistry. He is currently having a big challenge, “Drugging Undruggable Targets” by the targeted protein degradation technology with a proprietary RaPPIDS platform.

Kanae Gamo is leading overall operations of R&D activities as a CSO. She co-founded FIMECS with her colleagues in 2018 as a curve-out biotech from Takeda Pharmaceutical Company Limited. She started her career at Takeda in 2009. She has expertise in many techniques of molecular biology, genetics, epigenetics and next-generation sequencing in oncology and immunology areas. Through her nine years of pharmaceutical experience at Takeda, she increased responsibility of roles across target identification and validation. In parallel with FIMECS work, she got Ph.D. at University of Tsukuba in 2020. Utilizing proprietary drug discovery platform, RaPPIDS, to internal and collaborative programs, FIMECS seeks to provide life-saving medicine to patients all over the world.

Katsuhiro Uto enriches our board’s decision-making process with a fresh and impartial perspective as an external board member. His professional carrier began at Nippon Boehringer Ingelheim in 2005 as a senior research scientist, before broadening his expertise at two other Japanese specialty pharmaceutical companies. Throughout his carrier, he has been deeply involved in research and development, gaining significant expertise and achieving notable successes in respiratory, immunology, dermatology and pain management fields. He has also led numerous international research collaborations and strategic alliances. In 2021, He became a member of RaQualia Pharma, and since 2022, he has served as a Board Director, steering the company’s research and development efforts with visionary leadership.